Menu Search
Equities

Novoprotein Scientific Inc

688137:SHH

Novoprotein Scientific Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)29.67
  • Today's Change-0.04 / -0.13%
  • Shares traded74.38k
  • 1 Year change-41.03%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Novoprotein Scientific Inc's revenues fell -42.09% from 264.55m to 153.19m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 90.72m to 12.84m, a -85.84% decrease.
Gross margin64.49%
Net profit margin-6.10%
Operating margin-14.87%
Return on assets-0.37%
Return on equity-0.39%
Return on investment-0.38%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Novoprotein Scientific Inc fell by 65.65m. However, the company earned 69.16m from its operations for a Cash Flow Margin of 45.15%. In addition the company used 81.42m on investing activities and also paid 53.93m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share30.65
Tangible book value per share30.39
More ▼

Balance sheet in CNYView more

Novoprotein Scientific Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio23.75
Quick ratio22.83
Total debt/total equity0.0352
Total debt/total capital0.034
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.